Evidence map›Paper›PMID 26466957›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2015

T Cell Responses against Mycobacterial Lipids and Proteins Are Poorly Correlated in South African Adolescents.

Chetan Seshadri, Lin Lin, Thomas J Scriba, Glenna Peterson, David Freidrich, Nicole Frahm, Stephen C DeRosa, D Branch Moody, Jacques Prandi, Martine Gilleron and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Molecular recognition of microbial lipid-based antigens by T cells.Cellular and molecular life sciences : CMLS · 2018
    Review
  12. Article
  13. CD1b-restricted GEM T cell responses are modulated byProceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 3 countries.

Chetan SeshadriDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109; seshadri@u.washington.edu.
Lin LinVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109;
Thomas J ScribaSouth African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7700, South Africa; Department of Pediatrics and Child Health, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7700, South Africa;
Glenna PetersonDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109;
David FreidrichVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA 98109;
Nicole FrahmVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA 98109;
Stephen C DeRosaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; Department of Laboratory Medicine, University of Washington, Seattle WA 98109;
D Branch MoodyDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115;
Jacques PrandiInstitut de Pharmacologie et Biologie Structurale, Centre National de la Recherche Scientifique, Toulouse 31077, France; and.
Martine GilleronInstitut de Pharmacologie et Biologie Structurale, Centre National de la Recherche Scientifique, Toulouse 31077, France; and.
Hassan MahomedDivision of Community Health, Stellenbosch University, Stellanbosch 7602, South Africa.
Wenxin JiangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109;
Greg FinakVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109;
Willem A HanekomSouth African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7700, South Africa; Department of Pediatrics and Child Health, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7700, South Africa;
Raphael GottardoVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109;
M Juliana McElrathVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA 98109;
Thomas R HawnDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109;
Fred Hutch Cancer Center · USCancer Research Center · USUniversity of Washington · USInstitut de Pharmacologie et de Biologie Structurale · FRSouth African Tuberculosis Vaccine Initiative · ZABrigham and Women's Hospital · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAStellenbosch University · ZA

Funding

LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
HVTN Laboratory ProgramU01AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MCELRATH, MARGARET JULIANA · 2006 to 2010
$82.6M
Metabolomics Core U19AI111224 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI MOODY, DAVID BRANCH, MURRAY, MEGAN B · 2015 to 2021
$20.4M
T cell response to CDI-restricted lipids in tuberculosisR01AI049313 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI MOODY, DAVID BRANCH · 2001 to 2025
$10.6M
The Statistical and Computational Analysis of Flow Cytometry DataR01EB008400 · NIBIB · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOTTARDO, RAPHAEL · 2008 to 2015
$2.9M
Innate Immunogenetics & Human InfectionsK24AI089794 · NIAID · UNIVERSITY OF WASHINGTON · PI HAWN, THOMAS R · 2010 to 2014
$746k
The Role of CD1a in Protecting Against Human TuberculosisK08AI089938 · NIAID · UNIVERSITY OF WASHINGTON · PI SESHADRI, CHETAN · 2010 to 2014
$634k
NCI NIH HHS P30 CA015704NIAID NIH HHS K08 AI089938NIAID NIH HHS K08-AI89938NIAID NIH HHS K24 AI089794NIAID NIH HHS R01 AI049313NIAID NIH HHS U01 AI068618NIAID NIH HHS U01-AI068618NIAID NIH HHS U19 AI111224NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635NIBIB NIH HHS R01 EB008400
6 · The paper itself

Abstract

Human T cells are activated by both peptide and nonpeptide Ags produced by Mycobacterium tuberculosis. T cells recognize cell wall lipids bound to CD1 molecules, but effector functions of CD1-reactive T cells have not been systematically assessed in M. tuberculosis-infected humans. It is also not known how these features correlate with T cell responses to secreted protein Ags. We developed a flow cytometric assay to profile CD1-restricted T cells ex vivo and assessed T cell responses to five cell wall lipid Ags in a cross-sectional study of 19 M. tuberculosis-infected and 22 M. tuberculosis-uninfected South African adolescents. We analyzed six T cell functions using a recently developed computational approach for flow cytometry data in high dimensions. We compared these data with T cell responses to five protein Ags in the same cohort. We show that CD1b-restricted T cells producing antimycobacterial cytokines IFN-γ and TNF-α are detectable ex vivo in CD4(+), CD8(+), and CD4(-)CD8(-) T cell subsets. Glucose monomycolate was immunodominant among lipid Ags tested, and polyfunctional CD4 T cells specific for this lipid simultaneously expressed CD40L, IFN-γ, IL-2, and TNF-α. Lipid-reactive CD4(+) T cells were detectable at frequencies of 0.001-0.01%, and this did not differ by M. tuberculosis infection status. Finally, CD4 T cell responses to lipids were poorly correlated with CD4 T cell responses to proteins (Spearman rank correlation -0.01; p = 0.95). These results highlight the functional diversity of CD1-restricted T cells circulating in peripheral blood as well as the complementary nature of T cell responses to mycobacterial lipids and proteins. Our approach enables further population-based studies of lipid-specific T cell responses during natural infection and vaccination.

Indexed as

AdolescentAntigens, BacterialAntigens, CD1CD40 LigandCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell WallCross-Sectional StudiesFemaleFlow CytometryGlycolipidsHumansInterferon-gammaInterleukin-2K562 CellsLymphocyte ActivationAntigens, BacterialAntigens, CD1CD40 Ligandglucose mycolateGlycolipidsIL2 protein, humanInterferon-gammaInterleukin-2Membrane LipidsTumor Necrosis Factor-alpha

Identifiers

PMID26466957
PMCPMC4637215
OpenAlexW2411752254

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.